This study investigated the central haemodynamic, blood pressure (BP) and pulse wave responses to progressively increasing infusion rates of intravenous angiotensin II (Ang II) in normal volunteers during chronic therapy with telmisartan or placebo.
Introduction
Angiotensin receptor blockers (ARBs) reduce blood pressure (BP) by reducing systemic vascular resistance index (SVRI) while leaving cardiac index (CI) essentially unchanged. 1, 2 The central haemodynamic response to intravenous angiotensin II (Ang II) infusion in normal healthy volunteers is uncertain and the effects of progressively increasing infusion rates of intravenous Ang II on pulse wave characteristics during ARB therapy has not been adequately investigated.
Arterial pulse wave velocity, an index of arterial compliance, is becoming increasingly recognised as an independent risk factor for cardiovascular events. Ang II increases arterial pulse wave velocity, an effect which may be reduced by ARB therapy to a greater extent than can be explained by BP reduction alone. 3 The aim of this study was to investigate the central haemodynamic, BP and pulse wave responses to progressively increasing infusion rates of intravenous Ang II in normal volunteers during chronic ARB therapy using telmisartan and during placebo therapy.
Materials and methods

Study design
The study was of a double-blind, randomised, crossover design comparing BP, haemodynamic and pulse wave responses to Ang II in healthy young volunteers following one week of therapy with telmisartan, 40-80 mg daily, and one week of placebo therapy.The two treatment periods were separated by a wash out period of at least one week.
Drug therapy
Telmisartan, 40 mg, was inserted in capsules with lactose while matching placebo capsules were filled with lactose alone. The subjects were randomised to a treatment sequence of either telmisartan first and placebo second or placebo first and telmisartan second, with equal numbers in each sequence.The randomisation code was generated by the St. George Hospital Clinical Trials Pharmacist and the study was conducted in a double-blind manner.The subjects took one study capsule each day for the first two days. For the following five days, the subject took two capsules daily, if tolerated, during each of the one week treatment phases. If symptoms such as dizziness or hypotension occurred while taking two capsules a day, the dose was reduced to one capsule per day. During the placebo wash out phase, the subjects took one capsule each day. The capsules were taken in the morning at 0700-0800 hours. prior to randomisation, including the measurement of standing and lying BP. BP measurements and symptom assessments were made after the first two days of each treatment week and at the end of the placebo wash out phase. Measurements of CI, SVRI, BP, pulse wave reflection index (RI) and stiffness index (SI) responses to intravenous infusions of Ang II were made on the last day of each treatment phase in the morning, 2-4 hours after administration of study medication.
Interventions
A screening physical examination was performed
The subjects attended on each study day having consumed a standard breakfast of two slices of toast with a thin spread of margarine and having abstained from caffeine from 2400 hours the previous day. No alcohol was permitted during the preceding 24 hours.
Measurements of blood pressure, haemodynamic and pulse wave responses to angiotensin II
An indwelling cannula was inserted into an antecubital vein under local anaesthesia (2% lignocaine).A Finapres recorder (Finapres TM BP Monitor, Ohmeda 2300, Redmond, CA, USA) was placed on the index finger of the opposite hand for the continuous measurement of BP.A digital device for the measurement of indices of pulse wave velocity (Pulse Tracer, TAG Medical, Melbourne, VIC, Australia) was attached to the middle finger of the same hand.
A CardioDynamics (BioZ.com, San Diego, CA, USA) device was attached to the subject for the continuous indirect measurement of CI and SVRI using a trans-thoracic impedance measurement technique. This device measures trans-thoracic electrical impedance and ECG recordings simultaneously from four pairs of electrodes situated on either side of the chest and either side of the neck. Brachial BP is measured at one minute intervals from an arm cuff. Mean arterial pressure is calculated as diastolic BP (DBP) + (systolic BP [SBP]-DBP)/3. Synchronisation of ECG events with changes in trans-thoracic impedance allows estimation of stroke volume. Cardiac output (CO) is calculated as CO (L/minute) = heart rate x stroke volume/1,000. Systemic vascular resistance (SVR) is calculated as SVR (dynes x second/cm -5 ) = mean arterial pressure x 80/CO. CI (L/minute/m 2 ) and SVRI (dynes x second/cm -5 /m 2 ) were calculated by dividing CO and SVR respectively by body surface area. Body surface area was calculated as 0.007184 x weight (kg) 0.425 x height (cm) 0.725 . The measurement of CI using the Cardiodynamics Bioz.com device has been shown to correlate with measurements of CI using the thermal dilution method with correlation coefficients of around 0.77 and 0.84, respectively (p<0.001). [4] [5] The within-person, between-day reproducibility of the measurement of CI and SVRI for the Cardiodynamics BioZ.com device has been shown to be 6% and 7% respectively. 6 Indirect indices of the digital pulse wave were measured using a Pulse Tracer digital volume pulse measurement system (TAG Medical, Melbourne, VIC, Australia). The Pulse Trace uses a high fidelity photo-plethysmography transducer with a signal conditioning circuit to obtain a pulse waveform trace from the fingerbed. The transducer consists of a finger clip containing a light-emitting diode in one half and a photodiode receiver in the other half.The amount of blood present in the pulsatile vascular bed of the finger modulates the amount of light passing through the finger.This allows the display of an averaged volume pulse waveform. The pulse wave contour consists of two peaks, an initial (systolic) peak followed by a reflected (diastolic) peak. SI is calculated as the time interval between the two peaks divided by the subjects' height (m/second). SI is correlated with (r=0.65; p<0.0001), but not identical to pulse wave velocity. 7 The between-day, within-person variability of the measurement of SI using the Pulse Trace has been reported to be 9.6%. 7 RI is the ratio of the diastolic peak to the systolic peak (%).The RI is an index of pulse wave reflection that has been shown to be influenced by the administration of vasoactive drugs. 8 Following 15 minutes of supine rest and when BP and heart rate were stable, Ang II (0, 32, 64, 128, 256 and 512 ng/minute) was infused intravenously for 5 minutes at each infusion rate until BP changes were stable. CI, SVRI, BP, RI and SI were monitored continuously.
Infusions of Ang II were ceased if BP rose by more than 30 mmHg (systolic or diastolic), fell by more than 20 mmHg systolic, was less than 90 mmHg systolic or if the patient started feeling unwell.
Study population
Ten healthy, non-smoking male or female subjects, aged 18-40 years, who were receiving no medication and who usually consumed less than 40 g of alcohol on average per day were to be studied.
Prior to the study, all volunteers provided written, informed consent. The protocol was approved by the South Eastern Sydney Area Health Service Ethics Committee (Southern Section).
Exclusion criteria
Smokers and subjects with any chronic or recent illness, other than mild asthma or allergies not requiring oral therapy, were excluded from the study.
Data analysis and power calculation
The obtained data was analysed by repeated measures analysis of variance. Pairwise comparisons were made using Student's t-test with the Bonferroni correction. The data were analysed using the Statistica 6.0 Software Package (Statsoft, Tulsa, OK, USA). Using estimates of variance from previous studies in this department, a crossover study of 10 subjects was expected to have an 80% chance of detecting differences between placebo and telmisartan therapy of 15%. Changes equal to and greater than this were considered to be physiologically significant. Treatment order was included as an independent variable in the analysis to test for treatment-order interactions. Values 
Results
Characteristics of the subjects
Four males and six females aged 24+3 years (range 21-33 years) were studied.All subjects completed the study. All but one of the subjects successfully tolerated 80 mg telmisartan daily. The remaining subject was maintained on 40 mg telmisartan daily for the duration of the study because of low SBP and DBP on the 80 mg dose.
Cardiac index and systemic vascular resistance index responses to intravenous infusions of angiotensin II
Baseline CI measurements did not differ significantly between placebo and telmisartan therapy (3.30+0.95 and 3.28+0.72 L/minute/m 2 respectively; p=0.903).
There was a statistically significant, progressive increase in CI ( Figure 1 ) in response to intravenous infusions of Ang II on placebo therapy. Telmisartan significantly attenuated the increase in CI in response to Ang II (p=0.002) (Figure 1 ).
Baseline SVRI measurements did not differ significantly between placebo and telmisartan therapy (1984+532 and 1781+168 dyne.cm. second -5 respectively; p=0.307).
SVRI increased significantly in response to progressively increasing infusion rates of Ang II on placebo therapy. Telmisartan therapy significantly attenuated increases in SRVI in response to Ang II ( Figure 2 ).
Blood pressure and heart rate responses to intravenous infusions of angiotensin II
Baseline SBP measurements did not differ significantly between placebo and telmisartan therapy (110+16 and 101+15 mmHg respectively; p=0.128). In contrast, DBP was significantly lower on telmisartan than on placebo therapy (telmisar-tan 67+13; placebo 57+12 mmHg, p=0.047).
SBP increased significantly and progressively during increasing Ang II infusion rates on placebo. Telmisartan significantly attenuated the pressor responses to Ang II (Figure 3, p=0 .002).
Similar trends were observed for changes in diastolic and mean arterial BP in response to Ang II.
Baseline heart rates were similar on placebo (60+11 beats/minute) and telmisartan (65+7 beats/minute) (p=0.097).
The effects of angiotensin infusions on heart rate during placebo and telmisartan therapy appeared complex. On placebo, heart rate remained relatively constant during the first four infusion rates, fell at the second highest infusion rate, and then increased substantially at the highest infusion rate. In contrast, heart rate rose slowly but significantly with progressively increasing infusion rates of Ang II on telmisartan therapy (Figure 4, p=0 .0001). 
Reflection index and stiffness index responses to intravenous infusions of angiotensin II
Baseline RI values were significantly lower on telmisartan (34.8+18.6%) than on placebo (60.6+12.5%) therapy (p=0.030). RI increased significantly with increasing infusion rates of Ang II on placebo ( Figure 5 ). Telmisartan significantly attenuated the increase in RI during Ang II infusion.
SI tended to be lower on telmisartan therapy (5.11+1.02 m/second) than on placebo therapy (6.25+0.70 m/second) but the difference was not statistically significant (p=0.069).
SI increased progressively during increasing infusion rates of Ang II during placebo therapy. Telmisartan therapy significantly attenuated the increase in SI in response to Ang II ( Figure 6 , p=0.002).
No treatment-order interactions were found for any of the parameters analysed.
Discussion
This study demonstrated that blockade of angiotensin Type 1 (AT 1 -) receptors with telmisartan lowers baseline DBP and RI, and significantly attenuates the increase in CI, SVRI, RI and RI as well as BP responses to Ang II in normal volunteers. CI and SVRI both increased by approximately 25% at the maximum infusion rate of Ang II.These data suggest that increases in CI and SVRI both contribute significantly to the rise in BP in response to Ang II in normal volunteers, and that the effect is mediated via AT 1 -receptors.
Ang II may increase heart rate and CI by activation of presynaptic AT 1 -receptors on sympathetic nerves which facilitate noradrenaline release. 9 An increase in heart rate was observed in response to Ang II on placebo therapy, but only at the highest infusion rate of Ang II. Baroreceptor reflex activation may have complicated heart rate responses during Ang II infusion. In addition, AT 1 -and Type 2 (AT 2 -) receptors in animal hearts have been demonstrated to mediate positive chronotropic and inotropic responses to Ang II in vitro. 10, 11 However, there is evidence that positive inotropic and chronotropic responses mediated by post-synaptic angiotensin receptors occurs only in human atria and not in ventricular cardiomyocytes. 12, 13 It is uncertain to what extent these potential mechanisms contributed to the increase in CI during infusions of Ang II in this study. Reflex baroreceptor activation is unlikely to be responsible for increases in CI during Ang II infusion, as SVRI also rose in response to Ang II infusion. In fact, reflex baroreceptor activation may have dampened the inotropic and direct chronotropic effects of Ang II.
The observation that the increase in CI in response to Ang II was substantially attenuated by telmisartan therapy indicates that AT 1 -receptors play a significant role in the increase in CI in response to Ang II in healthy humans. As would be expected, AT 1 -receptor blockade prevented a rise in SVRI in response to Ang II. SI and RI responses to Ang II were also reduced during AT 1 -receptor blockade with telmisartan. However, it is unclear to what extent SI and RI were reduced due to AT 1 -receptor blockade per se or whether they were secondary to reductions in BP responses to Ang II.
A previous study using male volunteers evaluating the effects of valsartan on Ang II-mediated changes in pulse wave velocity found that blockade of AT 1 -receptors caused a fall in pulse wave velocity (RI and SI). 3 Ang II was administered at a single infusion rate.The study concluded that the decrease in pulse wave velocity during valsartan therapy could not be explained by blockade of the Ang II-induced rise in BP alone. The authors suggested that activation of the AT 2 -receptor could play a role in this response.The present study adds to these findings by demonstrating a dose-dependent increase in indices of pulse wave velocity (RI and SI) in response to increasing infusion rates of Ang II.
Baseline RI was significantly lower on telmisartan therapy compared with placebo and a significant reduction in the RI response to Ang II infusion occurred during telmisartan therapy. These results suggest that AT 1 -receptor blockade reduces pulse wave reflection in a similar manner to that observed during nitrate and β 2 -adrenoceptor agonist therapy. 8 The changes in RI observed during Ang II infusions suggest that Ang II produces dose-dependent increases in pulse wave reflection, an effect which is attenuated by telmisartan and therefore likely to be predominately mediated by AT 1 -receptors. The increase in SI observed during Ang II infusion suggests that Ang II increases large vessel stiffness, either directly or as a result of BP elevation, an effect which is attenuated by telmisartan therapy.
In conclusion,Ang II infusion not only increases BP and SVRI, but also causes dose-dependent increases in CI, RI and SI in healthy volunteers. Significant reductions in the CI, BP, SVRI, RI and SI responses to Ang II were demonstrated on telmisartan therapy compared with placebo.The results of the study suggest that increases in CI contribute significantly to BP responses to Ang II in healthy volunteers and that this effect appears to be mediated to a large extent by cardiac AT 1 -receptors.
Limitations of this study include the relatively low number of volunteers studied. However, this did not prevent the demonstration of statistically significant results. Furthermore, only normal volunteers were used. Differences may exist between normal volunteers and hypertensive volunteers. The length of treatment could also be of importance. In this study, the period of treatment was one week; it is not known whether long-term treatment would produce different results. Further studies are needed to address these issues. 
